Furthermore, we show that increased expression of immunogenic antigens leads to an increased ability for neoantigen- and CTA-specific CD8 cytotoxic T lymphocytes (CTL) to recognize and kill tumor cells in-vitro following treatment with DAC. The gene discussed is CD8A; the disease is neoplasm.